Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Kinase, CMGC MAPK | 0.2737 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.2737 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.2737 | 0.5 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.2737 | 0.5 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.2737 | 0.5 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.2737 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2737 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2737 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.2737 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2737 | 0.5 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.2737 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.2737 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.2737 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.2737 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.2737 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.2737 | 0.5 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.2737 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.2737 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.2737 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.2737 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 48.7 uM | Inhibition of 6His-tagged MDM2 (1 to 118) interaction to FITC-tagged p53 (17 to 26) (unknown origin) after 30 mins by fluorescence polarization assay | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.